Alecensa (alectinib) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Roche and Chugai. In some non-small cell lung cancer (NSCLC) patients, abnormal ALK configuration leads to the production of proteins that promote and maintain the malignant behavior of cancer cells. In vitro studies have shown that Alecensa may be a stronger inhibitor of ALK than Xalkori (crizotinib; Pfizer/Merck KGaA), the current standard-of-care in ALK-positive NSCLC. Alecensa has also demonstrated efficacy against secondary mutations, such as L1196M, C1156Y, and F1174L, which typically confer resistance to Xalkori. Furthermore, second-generation ALK inhibitors have shown the ability to cross the blood-brain barrier and act on tumors in the central nervous system, a common site for distant metastases in ALK-positive NSCLC.
4 Drug Overview
5 Product Profiles
5 Alecensa : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
14 Figure 83: Cemiplimab for non-small cell lung cancer – SWOT analysis
15 Figure 84: Datamonitor Healthcare’s drug assessment summary for cemiplimab in non-small cell lung cancer
17 Figure 85: Datamonitor Healthcare’s drug assessment summary for cemiplimab in non-small cell lung cancer
LIST OF TABLES 6 Table 1: Alecensa drug profile
7 Table 2: Alecensa pivotal trial data in non-small cell lung cancer
11 Table 3: Alecensa ongoing late-phase clinical trials in non-small cell lung cancer
18 Table 4: Alecensa sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 5: Alecensa patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.